Pancreatic Cancer Research

ResearcherUniversity of BonnActive in the last 2 years

Savita Bisht

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109149890. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer. Last author DOI 10.3390/ijms25116249↗
  2. Animal models for modeling pancreatic cancer and novel drug discovery. Co-author DOI 10.1080/17460441.2019.1566319↗
  3. Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. Co-author DOI 10.1159/000493437↗
  4. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000493868↗
  5. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. First author DOI 10.1186/s12885-017-3225-5↗
  6. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Co-author DOI 10.1186/s12951-016-0209-6↗
  7. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. First author DOI 10.1517/17460441.2011.534453↗
  8. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Co-author DOI 10.4161/cbt.11.11.15534↗
  9. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Georg Feldmann · 9 shared papers, 2011–2024 · strength 0.95
  2. Xuan Wang · 1 shared paper, 2024 · strength 0.24
  3. Nuh N. Rahbari · 1 shared paper, 2017 · strength 0.06
  4. Mathieu Pecqueux · 1 shared paper, 2017 · strength 0.06
  5. Bianca T. Hofmann · 1 shared paper, 2017 · strength 0.06
  6. Tristan Lerbs · 1 shared paper, 2017 · strength 0.06
  7. Christoph Reißfelder · 1 shared paper, 2017 · strength 0.06
  8. Sebastian Schölch · 1 shared paper, 2017 · strength 0.06
  9. Thilo Welsch · 1 shared paper, 2017 · strength 0.06
  10. Christoph Kahlert · 1 shared paper, 2017 · strength 0.06
  11. Jürgen Weitz · 1 shared paper, 2017 · strength 0.06
  12. Martin Schlesinger · 1 shared paper, 2016 · strength 0.06
  13. Stefan Holdenrieder · 1 shared paper, 2016 · strength 0.06
  14. Volker Fendrich · 2 shared papers, 2011 · strength 0.05
  15. Anirban Maitra · 2 shared papers, 2011 · strength 0.05
  16. Ute Schütte · 1 shared paper, 2011 · strength 0.04
  17. Marco Dal Molin · 1 shared paper, 2011 · strength 0.02
  18. Detlef Klaus Bartsch · 1 shared paper, 2011 · strength 0.02
  19. Barry D. Nelkin · 1 shared paper, 2011 · strength 0.02
  20. N.V. Rajeshkumar · 1 shared paper, 2011 · strength 0.02
  21. Niki A. Ottenhof · 1 shared paper, 2011 · strength 0.02
  22. Zeshaan A. Rasheed · 1 shared paper, 2011 · strength 0.02
  23. Manuel M. Hidalgo · 1 shared paper, 2011 · strength 0.02
  24. William H. Matsui · 1 shared paper, 2011 · strength 0.02
  25. Ignacio Garrido‐Laguna · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.